Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease

Yasuji Arase, Yusuke Kawamura, Yuya Seko, Mariko Kobayashi, Fumitaka Suzuki, Yoshiyuki Suzuki, Norio Akuta, Masahiro Kobayashi, Hitomi Sezaki, Satoshi Saito, Tetsuya Hosaka, Kenji Ikeda, Hiromitsu Kumada, Yuki Ohmoto-Sekine, Shiun Dong Hsieh, Kazuhisa Amakawa, Kyoko Ogawa, Naoki Matsumoto, Akiko Iwao, Hiroshi TsujiShigeko Hara, Yasumichi Mori, Minoru Okubo, Hirohito Sone, Tetsuro Kobayashi

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)


Aim: The aim of this case-control study was to assess the efficacy and safety of dipeptidyl peptidase-4 inhibitor (sitagliptin) for type 2 diabetes mellitus (T2DM) with non-alcoholic fatty liver disease (NAFLD). Methods: Twenty NAFLD patients with T2DM treated by sitagliptin were retrospectively enrolled as the sitagliptin group. These patients were given sitagliptin between January 2010 and July 2011. Another 20 NAFLD patients with T2DM treated only with diet and exercise for 48weeks were selected as the control group. Serum levels of fasting plasma glucose (FPG), hemoglobin A1C (HbA1c), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured before and 12, 24, 36 and 48weeks after the initiation of treatment. Results: In the sitagliptin group, average HbA1c levels decreased approximately 0.7% at 48weeks after the initiation of sitagliptin. Next, average FPG levels decreased approximately 15mg/dL at 48weeks after the initiation of sitagliptin. The serum levels of HbA1c and FPG in the sitagliptin group decreased with statistical significance compared to those in the control group (P<0.05). All the patients could take sitagliptin of 50mg/day without reduction necessitated by sitagliptin-related side-effects. There were no significant changes of average AST and ALT levels during follow up of 48weeks in both sitagliptin and control groups. Conclusion: Our results indicate sitagliptin is effective and safe for the treatment of T2DM complicated with NAFLD.

Original languageEnglish
Pages (from-to)1163-1168
Number of pages6
JournalHepatology Research
Issue number11
Publication statusPublished - Nov 2013
Externally publishedYes


  • Non-alcoholic fatty liver disease
  • Sitagliptin
  • Type 2 diabetes mellitus


Dive into the research topics of 'Efficacy and safety in sitagliptin therapy for diabetes complicated by non-alcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this